[P02BB01, trichlorfon, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Metrifonate.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL01, sulpiride, Scopolamine may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA01, tacrine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC03, terbutaline, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L04AX02, thalidomide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01AC01, thiotepa, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B02AB01, aprotinin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Tilidine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Scopolamine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.]
[A03AB12, mepenzolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA01, trihexyphenidyl, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03BB01, butylscopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Scopolamine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tyrothricin.]
[A10BH05, linagliptin, The metabolism of Scopolamine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Scopolamine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Scopolamine can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Scopolamine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Scopolamine can be decreased when combined with Viloxazine.]
[S01AA13, fusidic acid, The metabolism of Scopolamine can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE02, indinavir, The metabolism of Scopolamine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01ED01, crizotinib, The metabolism of Scopolamine can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ziprasidone.]
[G04BD07, tolterodine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J02AC03, voriconazole, The metabolism of Scopolamine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Scopolamine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Scopolamine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Scopolamine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Scopolamine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Scopolamine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Scopolamine.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE04, nelfinavir, The metabolism of Scopolamine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA02, donepezil, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AC06, thonzylamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Scopolamine.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Scopolamine.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AC01, benztropine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Scopolamine can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AP05, simeprevir, The metabolism of Scopolamine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A16AA07, metreleptin, The metabolism of Scopolamine can be increased when combined with Metreleptin.]
[A16AA06, betaine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Betaine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Scopolamine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Scopolamine is combined with Glycopyrronium.]
[N05CM19, suvorexant, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CX03, methacholine, Scopolamine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Scopolamine.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Naloxegol.]
[N04AA02, biperiden, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Scopolamine.]
[N06AX11, mirtazapine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Scopolamine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Scopolamine.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC05, isavuconazole, The metabolism of Scopolamine can be decreased when combined with Isavuconazole.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX52, venetoclax, The metabolism of Scopolamine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC01, buprenorphine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA03, rivastigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.]
[S01GX07, azelastine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Scopolamine.]
[L01EF02, ribociclib, The metabolism of Scopolamine can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE09, tipranavir, The metabolism of Scopolamine can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Scopolamine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Scopolamine can be decreased when combined with Efavirenz.]
[N04AA11, bornaprine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BX04, capsaicin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Scopolamine.]
[L02BB05, apalutamide, The metabolism of Scopolamine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Scopolamine can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Scopolamine.]
[A03AA03, camylofine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Scopolamine.]
[L01XX62, ivosidenib, The metabolism of Scopolamine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Scopolamine can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AA06, chlorphenoxamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.]
[R03BB08, revefenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Scopolamine.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Scopolamine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Scopolamine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Scopolamine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Scopolamine.]
[N07XX11, pitolisant, The serum concentration of Scopolamine can be decreased when it is combined with Pitolisant.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Scopolamine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Scopolamine.]
[N03AX25, cenobamate, The serum concentration of Scopolamine can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE05, amprenavir, The metabolism of Scopolamine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BD07, dronedarone, The metabolism of Scopolamine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Scopolamine.]
[A03AA08, dihexyverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dopexamine.]
[G04BD09, trospium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Scopolamine is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Scopolamine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Scopolamine is combined with Oliceridine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AF03, chlorprothixene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B06AC06, berotralstat, The metabolism of Scopolamine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Scopolamine can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Scopolamine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Fenozolone.]
[R03CC15, formoterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX73, sotorasib, The serum concentration of Scopolamine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Scopolamine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Scopolamine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Scopolamine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Scopolamine.]
[C01EB24, mavacamten, The serum concentration of Scopolamine can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H01AC08, somatrogon, The metabolism of Scopolamine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Scopolamine may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB10, hexocyclium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J01FA15, telithromycin, The metabolism of Scopolamine can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC02, itraconazole, The metabolism of Scopolamine can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC04, posaconazole, The metabolism of Scopolamine can be decreased when combined with Posaconazole.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Scopolamine.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC04, lofexidine, The therapeutic efficacy of Scopolamine can be increased when used in combination with Lofexidine.]
[R06AX13, loratadine, Scopolamine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Scopolamine.]
[A03AA04, mebeverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Mefenorex.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Scopolamine.]
[N04AA03, methixene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01XA18, cyclosporine, The metabolism of Scopolamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03XA02, conivaptan, The metabolism of Scopolamine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Moxonidine.]
[G03XA01, danazol, The metabolism of Scopolamine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX06, nefazodone, The metabolism of Scopolamine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.]
[G04BD08, solifenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S03BA01, dexamethasone, The metabolism of Scopolamine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA08, dexetimide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Scopolamine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Scopolamine is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AA07, dicyclomine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB14, pipenzolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08CA03, isradipine, The metabolism of Scopolamine can be decreased when combined with Isradipine.]
[A03AB11, poldine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Scopolamine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08DB01, diltiazem, The metabolism of Scopolamine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AB03, dimethindene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AA02, diphenhydramine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Reproterol.]
[C01BA03, disopyramide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.]
[S02AA12, rifamycin SV, The metabolism of Scopolamine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Scopolamine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD12, aprepitant, The metabolism of Scopolamine can be decreased when combined with Aprepitant.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Scopolamine.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dopamine.]
[N06AA16, dothiepin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Scopolamine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Scopolamine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Scopolamine.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CX07, edrophonium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD01, emepronium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Scopolamine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Scopolamine is combined with Topiramate.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB08, tridihexethyl, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA12, tropatepine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Scopolamine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Epinephrine is combined with Scopolamine.]
[N05CF02, zolpidem, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA02, ergotamine, The metabolism of Scopolamine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01AA17, erythromycin, The metabolism of Scopolamine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA05, profenamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A02BA04, nizatidine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, The metabolism of Scopolamine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Salbutamol.]
[G04BD02, flavoxate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[J02AC01, fluconazole, The metabolism of Scopolamine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V03AZ01, ethanol, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the sedative activities of Scopolamine.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE10, darunavir, The metabolism of Scopolamine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Scopolamine is combined with Eszopiclone.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA04, galantamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Alfentanil.]
[H04AA01, glucagon, Scopolamine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Scopolamine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Scopolamine.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AH04, quetiapine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Scopolamine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Scopolamine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Scopolamine can be decreased when combined with Nilvadipine.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.]
[R05DA03, hydrocodone, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.]
[G04BD06, propiverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Scopolamine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Scopolamine.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.]
[A03AA30, piperidolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AE01, buclizine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Scopolamine.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Scopolamine.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Scopolamine.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J04AC01, isoniazid, The metabolism of Scopolamine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AB02, ketoconazole, The metabolism of Scopolamine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Scopolamine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Arbutamine.]
[N04BC09, rotigotine, Scopolamine may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Labetalol is combined with Scopolamine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Scopolamine.]
[N07AA30, ambenonium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Scopolamine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Scopolamine.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C10AA02, lovastatin, The metabolism of Scopolamine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Scopolamine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Scopolamine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Scopolamine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Scopolamine.]
[P01BC02, mefloquine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DX01, memantine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Scopolamine.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB07, methantheline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H03BB02, methimazole, The metabolism of Scopolamine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Scopolamine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Methoxamine is combined with Scopolamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Scopolamine.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Scopolamine.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Scopolamine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Scopolamine.]
[S02AA13, miconazole, The metabolism of Scopolamine can be decreased when combined with Miconazole.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Scopolamine.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Scopolamine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX23, mitotane, The metabolism of Scopolamine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BD01, amiodarone, The metabolism of Scopolamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AB05, fosphenytoin, The metabolism of Scopolamine can be increased when combined with Fosphenytoin.]
[N04BC04, ropinirole, Scopolamine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Scopolamine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Scopolamine.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Scopolamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08CA04, nicardipine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Scopolamine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC05, pramipexole, Scopolamine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Scopolamine.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Nylidrin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB03, oxyphenonium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC01, pancuronium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD11, fesoterodine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Scopolamine can be increased when combined with Pentobarbital.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Scopolamine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Scopolamine.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Scopolamine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Scopolamine.]
[N03AB02, phenytoin, The metabolism of Scopolamine can be increased when combined with Phenytoin.]
[V03AB19, physostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE01, saquinavir, The metabolism of Scopolamine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A02BX03, pirenzepine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.]
[N02CX01, pizotyline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Scopolamine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Scopolamine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Scopolamine.]
[J05AE03, ritonavir, The serum concentration of Scopolamine can be increased when it is combined with Ritonavir.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Scopolamine is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[P01BA03, primaquine, The metabolism of Scopolamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Scopolamine can be increased when combined with Primidone.]
[C01BA02, procainamide, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA04, procyclidine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AD02, promethazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB05, propantheline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM06, propiomazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BA01, quinidine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J04AB02, rifampin, The metabolism of Scopolamine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07XX04, sodium oxybate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Scopolamine.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Scopolamine.]
[P02BB01, trichlorfon, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Metrifonate.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL01, sulpiride, Scopolamine may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA01, tacrine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tacrine.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC03, terbutaline, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Terbutaline.]
[N07XX06, tetrabenazine, The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Tetrabenazine.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L04AX02, thalidomide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01AC01, thiotepa, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B02AB01, aprotinin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Tilidine.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Scopolamine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Trazodone.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Scopolamine.]
[A03AB12, mepenzolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA01, trihexyphenidyl, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Scopolamine is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03BB01, butylscopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Scopolamine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01AA05, tyrothricin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Tyrothricin.]
[A10BH05, linagliptin, The metabolism of Scopolamine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Scopolamine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Scopolamine can be decreased when combined with Telaprevir.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Scopolamine can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Scopolamine can be decreased when combined with Viloxazine.]
[S01AA13, fusidic acid, The metabolism of Scopolamine can be decreased when combined with Fusidic acid.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE02, indinavir, The metabolism of Scopolamine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01ED01, crizotinib, The metabolism of Scopolamine can be decreased when combined with Crizotinib.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ziprasidone.]
[G04BD07, tolterodine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J02AC03, voriconazole, The metabolism of Scopolamine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Scopolamine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Scopolamine is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Scopolamine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Scopolamine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Scopolamine can be decreased when it is combined with Enzalutamide.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Scopolamine.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Octopamine.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE04, nelfinavir, The metabolism of Scopolamine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA02, donepezil, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AC06, thonzylamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Scopolamine.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Scopolamine.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Scopolamine.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AC01, benztropine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Scopolamine can be decreased when it is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Scopolamine is combined with Levomilnacipran.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AP05, simeprevir, The metabolism of Scopolamine can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A16AA07, metreleptin, The metabolism of Scopolamine can be increased when combined with Metreleptin.]
[A16AA06, betaine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Betaine.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Scopolamine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Scopolamine is combined with Glycopyrronium.]
[N05CM19, suvorexant, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CX03, methacholine, Scopolamine may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Scopolamine.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Naloxegol.]
[N04AA02, biperiden, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Scopolamine.]
[N06AX11, mirtazapine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[A03AA09, difemerine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Scopolamine is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Scopolamine.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC05, isavuconazole, The metabolism of Scopolamine can be decreased when combined with Isavuconazole.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX52, venetoclax, The metabolism of Scopolamine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC01, buprenorphine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA03, rivastigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.]
[S01GX07, azelastine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Scopolamine.]
[L01EF02, ribociclib, The metabolism of Scopolamine can be decreased when combined with Ribociclib.]
[R03CC12, bambuterol, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Bambuterol.]
[N07XX16, deutetrabenazine, The risk or severity of sedation and somnolence can be increased when Scopolamine is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Scopolamine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE09, tipranavir, The metabolism of Scopolamine can be decreased when combined with Tipranavir.]
[L01EX10, midostaurin, The metabolism of Scopolamine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Scopolamine can be decreased when combined with Efavirenz.]
[N04AA11, bornaprine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BX04, capsaicin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Scopolamine.]
[L02BB05, apalutamide, The metabolism of Scopolamine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Scopolamine can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Scopolamine.]
[A03AA03, camylofine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Scopolamine.]
[L01XX62, ivosidenib, The metabolism of Scopolamine can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Scopolamine can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AA06, chlorphenoxamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Scopolamine.]
[R03BB08, revefenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Scopolamine.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Esketamine.]
[J01FA09, clarithromycin, The metabolism of Scopolamine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Scopolamine.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Scopolamine.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Scopolamine.]
[N07XX11, pitolisant, The serum concentration of Scopolamine can be decreased when it is combined with Pitolisant.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Scopolamine.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Scopolamine.]
[N03AX25, cenobamate, The serum concentration of Scopolamine can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE05, amprenavir, The metabolism of Scopolamine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BD07, dronedarone, The metabolism of Scopolamine can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Scopolamine.]
[A03AA08, dihexyverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dopexamine.]
[G04BD09, trospium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Scopolamine is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Scopolamine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Scopolamine is combined with Oliceridine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AF03, chlorprothixene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Scopolamine.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B06AC06, berotralstat, The metabolism of Scopolamine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Scopolamine can be decreased when combined with Lonafarnib.]
[P03AX07, abametapir, The serum concentration of Scopolamine can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Fenozolone.]
[R03CC15, formoterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX73, sotorasib, The serum concentration of Scopolamine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Scopolamine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Scopolamine is combined with Citalopram.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Scopolamine can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Scopolamine.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Scopolamine.]
[C01EB24, mavacamten, The serum concentration of Scopolamine can be decreased when it is combined with Mavacamten.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H01AC08, somatrogon, The metabolism of Scopolamine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Scopolamine may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB10, hexocyclium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Homatropine.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J01FA15, telithromycin, The metabolism of Scopolamine can be decreased when combined with Telithromycin.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H01AX01, pegvisomant, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pegvisomant.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC02, itraconazole, The metabolism of Scopolamine can be decreased when combined with Itraconazole.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AC04, posaconazole, The metabolism of Scopolamine can be decreased when combined with Posaconazole.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Scopolamine.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC04, lofexidine, The therapeutic efficacy of Scopolamine can be increased when used in combination with Lofexidine.]
[R06AX13, loratadine, Scopolamine may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Scopolamine.]
[A03AA04, mebeverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Mefenorex.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Scopolamine.]
[N04AA03, methixene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Scopolamine.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01XA18, cyclosporine, The metabolism of Scopolamine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03XA02, conivaptan, The metabolism of Scopolamine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Moxonidine.]
[G03XA01, danazol, The metabolism of Scopolamine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX06, nefazodone, The metabolism of Scopolamine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.]
[G04BD08, solifenacin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S03BA01, dexamethasone, The metabolism of Scopolamine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA08, dexetimide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Scopolamine.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Scopolamine is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AA07, dicyclomine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB14, pipenzolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Pirbuterol.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08CA03, isradipine, The metabolism of Scopolamine can be decreased when combined with Isradipine.]
[A03AB11, poldine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Scopolamine can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08DB01, diltiazem, The metabolism of Scopolamine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AB03, dimethindene, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AA02, diphenhydramine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Scopolamine is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Reproterol.]
[C01BA03, disopyramide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Distigmine.]
[S02AA12, rifamycin SV, The metabolism of Scopolamine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Scopolamine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A04AD12, aprepitant, The metabolism of Scopolamine can be decreased when combined with Aprepitant.]
[R03AC12, salmeterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Scopolamine.]
[C01CA04, dopamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Dopamine.]
[N06AA16, dothiepin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Scopolamine.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Scopolamine.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Scopolamine.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CX07, edrophonium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Edrophonium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD01, emepronium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Scopolamine.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Scopolamine is combined with Topiramate.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB08, tridihexethyl, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA12, tropatepine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Tulobuterol.]
[N01AB04, enflurane, Enflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01FB02, ephedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Scopolamine can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of Tachycardia can be increased when Epinephrine is combined with Scopolamine.]
[N05CF02, zolpidem, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA02, ergotamine, The metabolism of Scopolamine can be decreased when combined with Ergotamine.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01AA17, erythromycin, The metabolism of Scopolamine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA05, profenamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A02BA04, nizatidine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, The metabolism of Scopolamine can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fluvoxamine.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Scopolamine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Salbutamol.]
[G04BD02, flavoxate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[J02AC01, fluconazole, The metabolism of Scopolamine can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V03AZ01, ethanol, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Flupentixol may increase the sedative activities of Scopolamine.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE10, darunavir, The metabolism of Scopolamine can be decreased when combined with Darunavir.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Scopolamine is combined with Eszopiclone.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DA04, galantamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Alfentanil.]
[H04AA01, glucagon, Scopolamine may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Scopolamine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Scopolamine.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AH04, quetiapine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Scopolamine.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Scopolamine.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Scopolamine can be decreased when combined with Nilvadipine.]
[C03AA03, hydrochlorothiazide, The serum concentration of Hydrochlorothiazide can be increased when it is combined with Scopolamine.]
[R05DA03, hydrocodone, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.]
[G04BD06, propiverine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Scopolamine.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Scopolamine.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Scopolamine is combined with Milnacipran.]
[A03AA30, piperidolate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AE01, buclizine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Scopolamine.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Scopolamine.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Scopolamine.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J04AC01, isoniazid, The metabolism of Scopolamine can be decreased when combined with Isoniazid.]
[R03CB01, isoproterenol, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J02AB02, ketoconazole, The metabolism of Scopolamine can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Scopolamine can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Arbutamine.]
[N04BC09, rotigotine, Scopolamine may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Labetalol is combined with Scopolamine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Scopolamine.]
[N07AA30, ambenonium, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Scopolamine.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Scopolamine.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C10AA02, lovastatin, The metabolism of Scopolamine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Scopolamine.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Scopolamine.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Scopolamine can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Scopolamine can be decreased when combined with Nilotinib.]
[N06AA21, maprotiline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Scopolamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Scopolamine.]
[P01BC02, mefloquine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06DX01, memantine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Scopolamine is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Scopolamine.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Scopolamine.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB07, methantheline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[H03BB02, methimazole, The metabolism of Scopolamine can be decreased when combined with Methimazole.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Scopolamine is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Methoxamine is combined with Scopolamine.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Scopolamine.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Scopolamine.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Scopolamine.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Scopolamine.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Scopolamine.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Scopolamine.]
[S02AA13, miconazole, The metabolism of Scopolamine can be decreased when combined with Miconazole.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Scopolamine.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Scopolamine.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XX23, mitotane, The metabolism of Scopolamine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BD01, amiodarone, The metabolism of Scopolamine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Ipratropium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N03AB05, fosphenytoin, The metabolism of Scopolamine can be increased when combined with Fosphenytoin.]
[N04BC04, ropinirole, Scopolamine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Scopolamine can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of CNS depression can be increased when Naphazoline is combined with Scopolamine.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Scopolamine.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Scopolamine is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Desvenlafaxine.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C08CA04, nicardipine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N07BA01, nicotine, The risk or severity of Tachycardia can be increased when Nicotine is combined with Scopolamine.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC05, pramipexole, Scopolamine may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01CA03, norepinephrine, The risk or severity of Tachycardia can be increased when Norepinephrine is combined with Scopolamine.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G02CA02, nylidrin, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Nylidrin.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Orciprenaline.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Scopolamine is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB03, oxyphenonium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03AC01, pancuronium, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[N05CC05, paraldehyde, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[G04BD11, fesoterodine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Pentazocine.]
[N05CA01, pentobarbital, The metabolism of Scopolamine can be increased when combined with Pentobarbital.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Scopolamine.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Phenoperidine.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Scopolamine.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Scopolamine.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Scopolamine.]
[N03AB02, phenytoin, The metabolism of Scopolamine can be increased when combined with Phenytoin.]
[V03AB19, physostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Physostigmine.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J05AE01, saquinavir, The metabolism of Scopolamine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A02BX03, pirenzepine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Scopolamine is combined with Piritramide.]
[N02CX01, pizotyline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Scopolamine can be decreased when combined with Delavirdine.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Scopolamine.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Scopolamine.]
[J05AE03, ritonavir, The serum concentration of Scopolamine can be increased when it is combined with Ritonavir.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Scopolamine is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[P01BA03, primaquine, The metabolism of Scopolamine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Scopolamine can be increased when combined with Primidone.]
[C01BA02, procainamide, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N04AA04, procyclidine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R06AD02, promethazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[A03AB05, propantheline, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CM06, propiomazine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Scopolamine is combined with Dextropropoxyphene.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Scopolamine can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C01BA01, quinidine, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Quinidine.]
[P01BC01, quinine, Quinine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[J04AB02, rifampin, The metabolism of Scopolamine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Scopolamine is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N07XX04, sodium oxybate, Scopolamine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Scopolamine.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Scopolamine.]
